Table II.
Current status of, and perspectives for, HT glycomics methods to dissect the human glycome.
| Current | Emerging | Future | ||
|---|---|---|---|---|
| Sample type | • Plasma • Serum • Urine |
• CSF • Saliva |
• Tissue • Cell lines |
• Single cells |
| Analyte | • N-glycans • Glycopeptides of a select set of isolated proteins in HT mode • Glycopeptides of complex mixtures in low throughput |
• O-glycans • Glycopeptides of a broader set of isolated proteins • Intact glycoproteins |
• Glycopeptides in complex matrices/mixturesa • GAGs • GSL glycans |
|
| Analytical depth | • N-glycan isomer information (limited) • Protein specificity • Site specificity |
• More extensive isomer information for all glycan types • Proteoform information (intact) |
• Isomer information at the glycopeptide level |
|
| Research field | • Biopharma • Preclinical • Biomedical • Specialized glycan labs |
• Clinical • Non-glycan specialized labs |
• Routine clinical diagnostics |
|
aRobust quantification in a HT manner of all glycopeptides in e.g. total plasma; CSF, cerebrospinal fluid; GAG, glycosaminoglycan; GSL, glycosphingolipid.